Transthera Sciences (Nanjing), Inc.
- Country
- ๐จ๐ณChina
- Ownership
- Holding
- Established
- 2014-04-15
- Employees
- 51
- Market Cap
- -
- Website
- http://www.transtherabio.com
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsCholangiocarcinoma
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Registration Number
- NCT06370013
- Locations
- ๐บ๐ธ
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
๐บ๐ธUniversity of Chicago Medical Center, Chicago, Illinois, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
- Conditions
- Cholangiocarcinoma Metastatic
- Interventions
- Drug: TT-00420 (tinengotinib)
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06057571
- Locations
- ๐จ๐ณ
Shandong Cancer Hospital, Jinan, Shandong, China
๐จ๐ณShenzhen Qianhai Shekou Free Trade Zone hospital, Shenzhen, Guangdong, China
๐จ๐ณCentral Hospital Affiliated to Shangdong First Medical University, Jinan, Shandong, China
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
- Conditions
- Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05948475
- Locations
- ๐บ๐ธ
UCLA Medical Center, Santa Monica, California, United States
๐บ๐ธThe University of Chicago Hospitals, Chicago, Illinois, United States
๐บ๐ธUMass Memorial Medical Center, Worcester, Massachusetts, United States
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
- Conditions
- B-Cell Malignancies
- Interventions
- Drug: TT-01488 Tablets
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05683717
- Locations
- ๐จ๐ณ
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: TT-00973-MS tablets treatment
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05673538
- Locations
- ๐จ๐ณ
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
๐จ๐ณAnhui Provincial Hospital, Hefei, Anhui, China
๐จ๐ณHunan Cancer Hospital, Changsha, Hunan, China
A Phase 1 Study of TT-00920 in Healthy Subjects
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05355129
- Locations
- ๐จ๐ณ
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05275504
- Locations
- ๐บ๐ธ
Gabrail Cancer Center, Canton, Ohio, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, United States
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Conditions
- Gallbladder CancerProstate CancerThyroid CancerAdvanced Solid TumorCholangiocarcinomaTriple Negative Breast CancerGastric CancerBiliary Tract CancerHER2-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT05253053
- Locations
- ๐จ๐ณ
Jilin Cancer Hospital, Changchun, Jilin, China
๐จ๐ณFudan Univisity Shanghai Cancer Center, Shanghai, China
๐จ๐ณShandong Cancer Hospital, Jinan, Shandong, China
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05043792
- Locations
- ๐บ๐ธ
Pharmaron CPC, Inc., Baltimore, Maryland, United States
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
- Conditions
- CholangiocarcinomaFGFR2 FusionFGFR2 Gene MutationFGFR1 AlterationFGFR3 Alteration
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04919642
- Locations
- ๐บ๐ธ
Methodist Dallas Medical Center, Dallas, Texas, United States
๐บ๐ธUT MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Cincinnati Cancer Institute, Cincinnati, Ohio, United States